ArticleHepatology (Baltimore, Md.)2026

Tumor site influences efficacy of MEKi and immunotherapy combinations in a preclinical model of cholangiocarcinoma.

Jacklyn N Hammons et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.